Our study adds to this body of work by showing that CAV1 expression is negatively correlated with TKI sensitivity across 785 human cancer cell lines, regardless of origin or mutation burden, suggesting a broader oncogenic role of CAV1 in promoting TKI resistance. This evidence concerns the gene CAV1 and cancer.